Standout Papers

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, ... 2008 2026 2014 2020 509
  1. Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 (2008)
    Dana D. Hu‐Lowe, Helen Y. Zou et al. Clinical Cancer Research

Citation Impact

3 by Nobel laureates 4 from Science/Nature 59 standout
Sub-graph 1 of 23

Citing Papers

Renal cell carcinoma
2024 Standout
Rational Design in Photopharmacology with Molecular Photoswitches
2023 StandoutNobel
6 intermediate papers

Works of Max Hallin being referenced

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
2008 Standout

Author Peers

Author Molecular Biology Oncology PRM Last Decade Papers Cites
Max Hallin 359 271 255 6 622
Hagai Meirovitch 1477 5 7 114 2.6k
J. Fred Pritchard 107 42 8 7 272
Maria Teresa Samà 61 58 12 18 289
Mustafa Grit 469 37 57 9 770
Xiaofan Su 99 28 69 15 240

All Works

Loading papers...

Rankless by CCL
2026